Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.

Trial Profile

Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Edoxaban (Primary) ; Acenocoumarol; Aspirin; Clopidogrel; Fluindione; Phenprocoumon; Prasugrel; Ticagrelor; Warfarin
  • Indications Embolism
  • Focus Therapeutic Use
  • Acronyms ENTRUST-AF-PCI
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 01 Feb 2018 Trial design and rationale were, published in the American Heart Journal.
    • 03 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 03 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top